Cerus Inc (CERS) - Long-Term Liabilities to Capital

Corporate emblem and logo of Cerus Inc (CERS)

The historical price chart for Cerus Corporation (CERS) reflects the trajectory of a company striving for global dominance through the implementation of INTERCEPT blood pathogen reduction technology. High business scalability is driven by the recurring sale of disposable components, with the indicator standing at 0.64. However, financial stability relies on a single product, meaning the brand's success depends directly on the speed of platform certification across new medical centers.

Cerus Corp - CERS Long-Term Debt to Capital (period 07/04/2022 - 11/01/2026)

Comprehensive metric breakdowns and analytics for Cerus Corporation (CERS)

- stock value and consensus price forecast:
Stock Quotes Cerus Corp.|CERS - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Cerus Corporation|CERS - Enterprise Value
- book value of equity indicators:
Equity per Share Cerus|CERS - Book Capitalization|Market Capitalization to Book Value cerus.com|CERS - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio Cerus Corporation|CERS - Long-Term Debt to Capital|Short-Term Debt to Capital cerus.com|CERS - Company Debts|Debt to Book Capitalization Ratio Cerus Corporation|CERS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Cerus|Interim Coverage Ratio cerus.com
- financial results and valuation multiples details:
CERS - Company Net Income
Comprehensive company analysis:Cerus Corp.
Signature product of Cerus Corporation

Fundamental asset selection requires an analysis of the liability structure to assess business resilience against long-term risks. This indicator measures the proportion of loans with a maturity exceeding one year relative to equity, which for Cerus Corporation (CERS), with its patent-protected monopoly in the blood safety systems niche, is reflected in the ratio of long-term loans to equity.

Competing companies

Long-Term Debt to Equity Ratio Intuitive Surgical, Inc. (ISRG)|Long-Term Debt to Capital DHR|BDX - Long-Term Liabilities to Capital|Long-Term Debt to Capital STE (STERIS plc)|WST: Long-Term Debt to Capital Ratio|Baxter - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Masimo Corp MASI|STVN: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Teleflex Corp|MMSI (Merit Medical Systems) - Long-Term Debt to Capital|Long-Term Debt to Capital envistaco.com|Long-Term Debt to Equity ICU Medical (ICUI)|Long-Term Debt to Equity XRAY (Dentsply Sirona Inc)|LeMaitre - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient ATRC|STAAR Surgical Company - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital ChromaDex Corp NAGE|ZimVie (ZIMV) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio ANGO|Long-Term Debt to Equity Alpha Teknova Inc|Monogram Orthopedics Inc. (MGRM) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio STSS (Sharps Technology, Inc.)|Long-Term Loans to Capital Ratio INFU|Long-Term Debt to Equity Utah Medical Products, Inc. UTMD|Long-Term Debt to Capital Coefficient KRMD|NYXH: Long-Term Debt to Equity Ratio|MBOT - Long-Term Debt to Capital|Pro-Dex, Inc. (PDEX) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio zentek.com|ELUT (Elutia) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Milestone Scientific Inc MLSS|Long-Term Debt to Equity NEXGEL, Inc (NXGL)|retractable.com - Long-Term Debt to Capital Ratio|Harvard Bioscience, Inc. - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio FEMY (femasys.com)|MHUA - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Predictive Oncology POAI|CJMB: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Atrion Corporation Inc.|NURO (NeuroMetrix, Inc.) - Long-Term Debt to Capital